睿知中国疾病研究地图
候选清单0

正在招募重症肌无力I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

ClinicalTrials.gov 上登记的一项重症肌无力开放试验,由空军军医大学唐都医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)空军军医大学唐都医院Tangdu Hospital西安医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06371040,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;

    入选标准第 12 条

    If you are a woman of childbearing potential (WOCBP), you must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CART for the first time.

    入选标准第 13 条

    Women who are lactating or pregnant, or women who plan to become pregnant at any time within 12 months after receiving CART treatment, or who have a history of spontaneous abortion or induced abortion within 4 weeks before screening;

    排除标准第 3 条

    Study participants have received rituximab treatment within 6 months before screening;

    排除标准第 7 条

    Have received tocilizumab or eculizumab treatment within 3 months before screening;

    排除标准第 8 条

    Have received intravenous human immunoglobulin, plasma exchange, or immunotherapy within 4 weeks before screening;

    排除标准第 9 条

  3. Elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)).

    排除标准第 13 条

    Total bilirubin>1.5 times ULN

    排除标准第 14 条

    Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2

    排除标准第 15 条

    Abnormal PT or INR, or prolonged APTT >1.5 times ULN

    排除标准第 16 条

    Neutrophil count <1000cell/ul

    排除标准第 17 条

    Platelet count <50000/mm3

    排除标准第 18 条

    Hemoglobin<8.0g/dl

    排除标准第 19 条

  4. Known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06371040,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Study participants will be selected for this study only if they meet all of the following criteria:
  2. Age ≥18 years old and ≤80 years old;
  3. The subject signs the informed consent form, is willing and able to comply with the protocol, complete the research assessment and return for follow-up;
  4. To be diagnosed as a patient with systemic MG, the patient is required to have positive myasthenia-related antibodies (AChR-Ab, Musk-Ab or LRP4) on the basis of typical myasthenic symptoms;
  5. Evaluated by the researcher as refractory MG. Refractory MG is defined as:
  6. Treatment failed after receiving at least 2 immunosuppressants
  7. Definition of treatment failure: 1) Persistent weakness and impairment of daily activities; 2) MG aggravation and/or crisis during treatment; 3) Intolerance to immunotherapy due to side effects or comorbidities;
  8. Repeated plasma exchange (PE) or intravenous immune globulin (IVIg) treatment is required to control symptoms;
  9. The researchers believe that despite the current routine immunotherapy for patients, MG still imposes a large functional burden on patients.
  10. MGFA classification IIa\~IVa at screening and baseline;
  11. QMGS score ≥11 points or MG-ADL score ≥5 points at screening and baseline, of which the eye score accounts for no more than 50%;
  12. Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;
  13. If you are a woman of childbearing potential (WOCBP), you must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CART for the first time.

排除标准:Exclusion Criteria:

  1. Prior to screening and the baseline visit, study participants will not be eligible for inclusion in the study if they meet any of the following criteria:
  2. The researcher believes that there is any medical or mental condition that may harm the research participant or affect the research participant's ability to participate in this study; or any condition that the researcher believes is related to poor compliance;
  3. Women who are lactating or pregnant, or women who plan to become pregnant at any time within 12 months after receiving CART treatment, or who have a history of spontaneous abortion or induced abortion within 4 weeks before screening;
  4. Study participants have clinically relevant active infections (such as sepsis, pneumonia or abscess) or serious infections (resulting in hospitalization or requiring antibiotic treatment) within 4 weeks before screening;
  5. thymoma that underwent thymectomy within 6 months before baseline or was planned to undergo thymectomy during the study, or required chemotherapy and/or radiotherapy at any time;
  6. Investigator participants have received live attenuated vaccine vaccination within 8 weeks before screening; or plan to receive live vaccine vaccination within 8 weeks after treatment;
  7. Study participants have received rituximab treatment within 6 months before screening;
  8. Have received tocilizumab or eculizumab treatment within 3 months before screening;
  9. Have received intravenous human immunoglobulin, plasma exchange, or immunotherapy within 4 weeks before screening;
  10. Those with known serious underlying diseases, such as liver and kidney damage, blood diseases, previous severe cardiovascular disease, severe hypertension, diabetes, and poor blood pressure and blood sugar control;
  11. Unresected thymoma (Note: Subjects with benign thymoma resected more than one year before screening are eligible. Benign is defined as no known metastasis on pathological examination and no intracystic or extracystic Extension. Imaging studies must be performed during the screening period to assess thymic status).
  12. Any of the following laboratory abnormalities occur during the screening period (one repeat measurement can be performed during the screening period before randomization to confirm the results)
  13. Elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)).
  14. Total bilirubin>1.5 times ULN
  15. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
  16. Abnormal PT or INR, or prolonged APTT >1.5 times ULN
  17. Neutrophil count <1000cell/ul
  18. Platelet count <50000/mm3
  19. Hemoglobin<8.0g/dl
  20. Those with a high-risk history of tuberculosis infection or acquired tuberculosis infection;
  21. Known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;
  22. Positive for hepatitis B surface antigen (HBsAg) during the screening period;
  23. Receive blood transfusion treatment 4 weeks before screening or during the screening period;
  24. Symptoms worsen rapidly during the lead-in period and enter crisis or pre-crisis state (MGFA IVb-V)
  25. Other circumstances in which the researcher deems it inappropriate to participate in the study.

引自 ClinicalTrials.gov, NCT06371040, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06371040,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06371040